Last reviewed 2026-06-10 · How we verify

Deficiency of aromatic-L-amino-acid decarboxylase — Treatment Landscape & Competitive Intelligence

Deficiency of aromatic-L-amino-acid decarboxylase (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Deficiency of aromatic-L-amino-acid decarboxylase, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. PTC Therapeutics International Limited · 1 drug in Deficiency of aromatic-L-amino-acid decarboxylase

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Deficiency of aromatic-L-amino-acid decarboxylase:

• Deficiency of aromatic-L-amino-acid decarboxylase treatment updates — RSS
• Deficiency of aromatic-L-amino-acid decarboxylase treatment updates — Atom
• Deficiency of aromatic-L-amino-acid decarboxylase treatment updates — JSON

Cite this brief

Drug Landscape (2026). Deficiency of aromatic-L-amino-acid decarboxylase — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/deficiency-of-aromatic-l-amino-acid-decarboxylase. Accessed 2026-06-10.

Related

• Deficiency of aromatic-L-amino-acid decarboxylase full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing